

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM441729

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cypress Bioscience Inc.		08/29/2017	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Exagen Diagnostics, Inc.		
Street Address:	1261 Liberty Way		
Internal Address:	Suite C		
City:	Vista		
State/Country:	CALIFORNIA		
Postal Code:	92081		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	3865020	AVISE	
Registration Number:	3865042	AVISE MCV	
Registration Number:	3865041	AVISE PG	
CORRESPONDENCE DATA			
Fax Number:	3129130002		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	312 913 0001		
Email:	allen@mbhb.com		
Correspondent Name:	McDonnell Boehnen Hulbert & Berghoff LLP		
Address Line 1:	300 South Wacker Drive, Suite 3100		
Address Line 4:	Chicago, ILLINOIS 60606		
NAME OF SUBMITTER:	David Harper		
SIGNATURE:	/David Harper/		
DATE SIGNED:	09/01/2017		
Total Attachments: 3			
source=ConfirmationofTerminationof#page1.tif			
source=ConfirmationofTerminationof#page2.tif			
source=ConfirmationofTerminationof#page3.tif			

OP \$90.00 3865020

TERMINATION OF SECURITY INTEREST IN TRADEMARKS AND PATENTS

WHEREAS Exagen Diagnostics, Inc., a Delaware corporation with a principal office at 1261 Liberty Way, Suite C, Vista, CA 92081 (the "**Grantor**"), is the owner or licensee of record of the trademarks and applications, now issued or pending in the United States Patent and Trademark Office; and is the owner of record of the patents and patent applications **B**, now issued or pending in the United States Patent and Trademark Office (collectively the "IP"), listed in Exhibit A; and

WHEREAS, the Grantor entered into that certain Security Agreement dated as of October 12, 2010 (the "**Security Agreement**"), between the Grantor and Royalty Pharma Collection Trust ("**Secured Party**"), as successor to Cypress Bioscience Inc. ("**Cypress**"), formerly having a place of business at 4350 Executive Drive, Suite 325, San Diego, California 92121, a true and correct copy of which was recorded by the United States Patent and Trademark Office on June 2, 2010, at Reel 025126, Frame 0245;

WHEREAS, the Secured Party's assets were acquired by the Grantor on October 8, 2010;

WHEREAS, in 2011 Cypress was dissolved and the Secured Party succeeded to all of the Cypress's assets;

WHEREAS Grantor represents that the Note that was secured by the IP, as well the other conditions to release of the security interest in Amendment Number 4 to the Asset Purchase Agreement between Grantor and the Secured Party, executed on October 8, 2013, have been satisfied;

WHEREAS, the Secured Party desires to release its security interest in the IP and terminate the Security Agreement;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Secured Party hereby:


1. releases and reassigns to the Grantor any and all liens, security interests, right, title and interest of Secured Party pursuant to the Security Agreement in the IP more fully described on Exhibit A, without recourse or representation or warranty, express or implied; and
2. authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the release hereby given.

IN WITNESS WHEREOF, Secured Party has caused this Termination of Security Interest in Trademarks and Patents to be signed by its duly authorized representative as of this 29th day of August 2017.

Secured Party:

Royalty Pharma Collection Trust,
As successor to Cypress Bioscience Inc.

By: RP Management, LLC,
As Administrator of
Royalty Pharma Collection Trust

By: 


Name: George W. Lloyd

Title: EVP & General Counsel

SCHEDULE B

TRADEMARK	COUNTRY	APP. NO./ FILING DATE	REG NO./ ISSUE DATE	GOODS/SERVICES	STATUS
AVISE	U.S.	7551794 August 20, 2008	N/A	Class 42: Medical laboratory services, namely, laboratory testing, evaluation and research services; medical laboratory services, namely, disease management and pathology services; medical laboratory services, namely, providing medical laboratory information to health care providers, managed care providers and patients via global computer networks; medical and clinical chemical laboratory services used by medical professionals for diagnosis, disease stratification, prognosis, therapy selection and therapy monitoring. Class 44: Health care for treating rheumatological, neurological, immunological, oncological and hematological disorders and pain management; providing medical and health information on the treatment of rheumatological, neurological, immunological, oncological and hematological disorders and pain management.	PENDING; ALLOWED Filed ITU application August 20, 2008; Office Action issued December 1, 2008; Response Filed; Published for Opposition July 14, 2009; Notice of Allowance issued October 6, 2009; Statement of Use filed.
AVISE MCY	U.S.	77567183 September 18, 2008	N/A	Class 42: Medical laboratory services, namely, laboratory testing, evaluation and research services; medical laboratory services, namely, disease management and pathology services; medical laboratory services, namely, providing medical laboratory information to health care providers, managed care providers and patients via global computer networks; medical and clinical chemical laboratory services used by medical professionals for diagnosis, disease stratification, prognosis, therapy selection and therapy monitoring; medical laboratory	PENDING; ALLOWED Filed ITU application August 20, 2008; Office Action issued December 1, 2008; Response Filed; Published for Opposition July 14, 2009; Notice of Allowance issued October 13, 2009; Statement of Use filed.

REEL: 025126 FRAME: 0254
PATENT

TRADEMARK	COUNTRY	APP. NO./ FILING DATE	REG NO./ ISSUE DATE	GOODS/SERVICES	STATUS
				antibody testing services for detecting mutated citrullinated vimentin; medical laboratory services for detecting, providing prognosis and monitoring rheumatoid arthritis disease in patients Class 44: Medical antibody testing services for detecting mutated citrullinated vimentin; medical testing services for detecting, providing prognosis and monitoring rheumatoid arthritis disease in patients	
AVISE PG (Stylized) 	U.S.	77567181 September 19, 2008	N/A	Class 42: Medical laboratory services, namely, laboratory testing, evaluation and research services; medical laboratory services, namely, disease management and pathology services; medical laboratory services, namely, providing medical laboratory information to health care providers, managed care providers and patients via global computer networks; medical and clinical chemical laboratory services used by medical professionals for diagnosis, disease stratification, prognosis, therapy selection and therapy monitoring; medical laboratory testing services relating to methotrexate polyglutamates for monitoring and predicting responses to methotrexate in patients with autoimmune diseases; medical laboratory services relating to methotrexate polyglutamates for monitoring and predicting responses to methotrexate in patients with autoimmune diseases Class 44: Medical testing services relating to methotrexate polyglutamates for monitoring and predicting responses to methotrexate in patients with autoimmune diseases	PENDING; ALLOWED Filed ITD application August 20, 2008; Office Action issued December 1, 2008; Response Filed; Published for Opposition July 14, 2009; Notice of Allowance issued October 6, 2009; Statement of Use filed

REEL: 025126 FRAME: 0255 PATENT

688672 v5183